They are an up-and-coming company in a bandage/wound healing space that has little innovation. If their product works, this is a $500 million buyout or partnership with Johnson & Johnson.
AC5 will not only be used in surgery, but also with primary care physicians, in households, first aid, etc. This is a great opportunity.
Sentiment: Strong Buy